Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Radiation Oncology
•
Lymphoma
•
Internal Medicine
•
Hematology
Would you recommend consolidative radiation therapy to an isolated frontal dural MALT lymphoma after complete response to chemotherapy?
Answer from: Radiation Oncologist at Community Practice
I would treat this with ISRT principles with generous dural margins to 24-30 Gy.
Sign in or Register to read more
6207
Related Questions
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
What dose and fractionation would you deliver to the sole of the foot in a patient with multifocal cutaneous DLBCL that is resistant to systemic therapy?